Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.85 USD
Change Today -0.19 / -2.36%
Volume 232.2K
NWBO On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

northwest biotherapeutics (NWBO) Snapshot

Open
$7.97
Previous Close
$8.04
Day High
$8.06
Day Low
$7.76
52 Week High
04/17/15 - $9.45
52 Week Low
10/10/14 - $3.79
Market Cap
603.6M
Average Volume 10 Days
269.9K
EPS TTM
$-1.97
Shares Outstanding
76.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NORTHWEST BIOTHERAPEUTICS (NWBO)

Related News

No related news articles were found.

northwest biotherapeutics (NWBO) Related Businessweek News

No Related Businessweek News Found

northwest biotherapeutics (NWBO) Details

Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. The company’s products include DCVax-L, which is under Phase III brain cancer trial for treating brain and ovarian cancer; DCVax-Direct that is under Phase I/II clinical trial for various types of inoperable solid tumor cancers; and DCVax-Prostate for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

12 Employees
Last Reported Date: 03/17/15
Founded in 1996

northwest biotherapeutics (NWBO) Top Compensated Officers

Chairperson, Chief Executive Officer, Preside...
Total Annual Compensation: $500.0K
Founder, Chief Scientific Officer, Secretary ...
Total Annual Compensation: $325.0K
Senior Vice President of Clinical Research
Total Annual Compensation: $300.0K
Chief Technical Officer
Total Annual Compensation: $425.0K
Senior Vice President of Business Development
Total Annual Compensation: $425.0K
Compensation as of Fiscal Year 2014.

northwest biotherapeutics (NWBO) Key Developments

Northwest Biotherapeutics, Inc. Presents at Virtual Investor Conferences, May-07-2015 12:15 PM

Northwest Biotherapeutics, Inc. Presents at Virtual Investor Conferences, May-07-2015 12:15 PM. Speakers: Linda F. Powers, Chairperson, Chief Executive Officer, President, Chief Financial Officer and Principal Accounting Officer.

Northwest Denies To Be A Possible Acquisition Target

Northwest Biotherapeutics, Inc. (NasdaqCM:NWBO) denies to be a possible acquisition target. Linda Powers, Chief Executive Officer of Northwest Biotherapeutics said being bought out isn’t the ideal plan.

Northwest Biotherapeutics, Inc. announced delayed annual 10-K filing

On 03/16/2015, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NWBO:US $7.85 USD -0.19

NWBO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NWBO.
View Industry Companies
 

Industry Analysis

NWBO

Industry Average

Valuation NWBO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 338.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 354.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NORTHWEST BIOTHERAPEUTICS, please visit www.nwbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.